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Background & Aims:
Gene silencing via promoter hypermethylation is a central event in the pathogenesis of cancers. To identify novel methylation targets in colon cancer, we conducted a genome-wide, microarray-based, in silico, and epigenetic search. Methods: Complementary DNA microarray experiments were first performed to identify genes down-regulated in primary colon cancers and up-regulated in colon cancer cell lines after global DNA demethylation by 5-aza-2=-deoxycitidine. Candidate methylation targets were then identified by combining these microarray data with in silico genetic and functional searches. Candidate genes recognized by these searches were further investigated for promoter hypermethylation in colon cancer using methylationspecific polymerase chain reaction. Results: We identified 51 novel and 3 known candidate methylation targets. Subsequent epigenetic analysis revealed that primary colon cancers demonstrated frequent methylation of somatostatin (SST, 30 of 34 cases, 88%) and the substance P precursor gene tachykinin-1 (TAC1; 16 of 34 cases, 47%). TAC1 methylation intensity was significantly higher in Dukes A/B than in Dukes C/D cancers (P ϭ .01). SST methylation intensity was significantly higher in low-level microsatellite instability (MSI-L) than in non-MSI-L cancers (P ϭ .02). Methylation was associated with messenger RNA down-regulation for both SST and TAC1. Furthermore, we isolated 5 additional novel promoter methylation targets: NELL1, AKAP12, caveolin-1, endoglin, and MAL. Conclusions: These data strongly suggest that SST and TAC1 are involved in colon carcinogenesis. Further studies are now indicated to elucidate mechanisms underlying their involvement in colon cancer and their values as clinical biomarkers. NELL1, AKAP12, caveolin-1, endoglin, and MAL are also promising tumor suppressor gene candidates deserving of further study. I n the United States, colon cancer is the most prevalent malignancy and the leading cause of death among digestive system diseases. 1 To establish novel therapeutic and diagnostic strategies against this deadly disease, it is essential to understand its molecular pathology. One of the key molecular pathogenic elements underlying human cancer is inactivation of tumor suppressor genes. Inactivation of tumor suppressor genes is frequently due to promoter hypermethylation. 2 Therefore, cancer-specific promoter hypermethylation can itself serve as a valuable clue to uncover novel tumor suppressor genes.
In this context, we conducted a genome-wide search for novel targets of promoter hypermethylation in colon cancers by utilizing a 2-pronged microarray-based and in silico gene-filtering method. Herein, we report the results of this search and subsequent epigenetic validation. Seven novel genes were identified as targets of promoter hypermethylation-induced gene silencing in primary colon cancers. Most notably, 2 of these 7 novel genes were well-characterized gastrointestinal neuroendocrine and growth-regulatory peptide genes: somatostatin (SST) and the gene encoding precursor for neuroendocrine peptides such as substance P, tachykinin-1 (TAC1).
Neuroendocrine peptides play essential roles in the regulation of gastrointestinal endocrine and exocrine secretion, motility, and mucosal immunity. Moreover, some neuroendocrine peptides, including SST, have been implicated in the modulation of human tumorigenesis by both direct and indirect means. 3, 4 The current findings provide novel direct epigenetic evidence in human patients for the involvement of SST and TAC1 in the process of human colon tumor suppression.
Materials and Methods Materials
Fifty-six primary human colon cancers, 22 noncancerous human colon mucosae, and 14 human colon cancer cell lines were included in this study. Colonic tissues were macroscopically dissected to enrich colonic mucosal layers or tumor cells. Genomic DNA and total RNA were extracted from snapfrozen tissues. Tumor microsatellite instability (MSI) status was determined based on 11 microsatellite markers as described previously. 5 Briefly, specimens with MSI at 30% or more of informative loci were labeled as microsatellite unstable (MSI-H), specimens showing MSI at less than 30% of informative loci were labeled as having low-level microsatellite instability (MSI-L), and specimens with no MSI were labeled as microsatellite stable (MSS). The clinicopathologic characteristics of the cases are summarized in Table 1 . All colonic tissues were selected from our tissue repository based on the availability of a sufficient amount of high-quality nucleic acids (DNA and/or RNA), clinicopathologic data, and informative MSI data at more than 5 microsatellite loci including BAT25 and BAT26. This tissue repository contained surgically resected colonic tissues at the University of Maryland, Baltimore, and the Baltimore VA Hospital collected under institutional review board (IRB) approval and with informed consent. The current study was approved by the IRB at the University of Maryland at Baltimore.
5-Aza-2-deoxycitidine Treatment
Colon cancer cell lines HT29 and HCT116 were seeded at a density of 4 ϫ 10 5 cells per 75-cm 2 culture flask and incubated for 24 hours in growth media. The cells were then treated with 5-aza-2-deoxycitidine (5-aza-dC) in either of the following conditions: (1) 10 mol/L 5-aza-dC for 84 hours or (2) 1 mol/L 5-aza-dC for 24 hours followed by 60 hours of 5-aza-dC-free growth. These 2 5-aza-dC treatment regimens were employed to obtain expression data under diverse cellular conditions: the former regimen focused on maximum DNA demethylation, and the latter regimen focused on moderate DNA demethylation to minimize damage to cell viability.
cDNA Microarray Analysis
Complementary DNA (cDNA) microarray analysis using an in-house 8064 human gene microarray was performed as described previously. 5 In brief, 30 g of total RNA were amplified using a T7-based protocol, and 6 g of the resulting amplified RNA (aRNA) were labeled with Cy5-dCTP. An aRNA pool of human cancer cell lines was used as the reference probe and labeled with Cy3-dCTP. The expression level of each gene was represented by the log-transformed Cy5-Cy3 intensity ratio, and global intensity-based normalization was performed. 6 To identify genes that were down-regulated in colon cancers relative to normal colonic mucosae, we performed significance analysis of microarray (SAM) comparing 7 normal colonic mucosae to 12 MSI-H colon cancers or to 15 MSS colon cancers. A gene was excluded from SAM analysis when it lacked expression data in more than 30% of the normal tissue group or the tumor group. Differentially expressed genes were determined at a false discovery rate (FDR) of less than 12%.
To identify genes that were up-regulated by 5-aza-dC treatment in HCT116 and/or HT29, we calculated the log-transformed ratio of the expression level for the pretreatment specimen relative to that of the posttreatment specimen. A gene was classified as up-regulated by 5-aza-dC treatment when this value was greater than 0.75 (equivalent to 1.65-fold up-regulation) in at least 1 treatment condition in at least 1 cell line. Genes with very low expression levels in posttreatment specimens were eliminated from further analyses. The cut-off criterion was defined as median signal intensity less than median background intensity plus 1 standard deviation (SD).
In Silico Search
The presence of a CpG island overlapping the 5= untranscribed region (5=-UTR) or first exon of a target gene was examined using the USCS Human Genome Browser database (www.genome.ucsc.edu/cgi-bin/hgGateway) according to its CpG island definition. The presence of a putative promoter within target CpG islands was verified using WWW Promoter Scan (bimas.dcrt.nih.gov:80/molbio/proscan/) and the Eukaryotic Promoter Database (http://www.epd.isb-sibch/index.html). The putative function of a target gene was obtained using the SWISS-Prot (au.expasy.org/sprot), the Entrez Gene (www. ncbi.nlm.nih.gov/entrez/query.fcgi?dbϭgene), and the FatiGO databases (www.fatigo.org).
Real-Time MSP
Bisulfite treatment of genomic DNA was performed according to a standard protocol. 7 A PCR amplicon to detect the fully methylated allele for each gene was designed within a CpG island overlapping the 5=-UTR. CpGenome Universal Methylated DNA (Chemicon International, Temecula, CA) was used as a positive control. Real-time qualitative MSP was performed on an iCycler (Bio-Rad, Hercules, CA) using iQ Supermix SYBR Green (Bio-Rad). Presence of the PCR product corresponding to the methylated allele was determined based on the melting curve profile of each specimen. Real-time quantitative MSP with a TaqMan probe was performed on an ABI7700 Sequence Detector System (Applied Biosystems, Foster City, CA) using iQ Supermix (Bio-Rad). Duplex PCR with a ␤-actin (ACTB) primer and probe sequences containing no CpGs was performed for normalization. For both qualitative and quantitative MSP, 50 cycles of PCR amplification were performed according to the manufacturer's protocol. A methylation index (MI), representing the ratio of densely methylated DNA in the sample at the target sequence relative to the fully methylated positive control, was calculated as follows:
where Ts and Tc represent levels of target gene methylation in the sample and the control DNA, respectively, and As and Ac correspond to the amplified ACTB level in the sample and the control DNA, respectively. The cut-off value of methylated allele ratio for positive methylation was defined as 0.20. Primer and probe sequences are listed in Table 2 .
Real-Time Quantitative ReverseTranscription Polymerase Chain Reaction
Real-time quantitative 1-step reverse-transcription polymerase chain reaction (RT-PCR) was performed on an ABI7700 using Quantitect Probe RT-PCR kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol. ACTB was analyzed as well for normalization of data. Total RNA from a normal colonic mucosal specimen was used as the quantification standard specimen. An expression index (EI), representing the relative expression level of target mRNA to the standard specimen, was calculated according to the following formula:
where Ts and Tc represent levels of mRNA expression for the target gene in the sample and control cDNA, respectively, and As and Ac correspond to the amplified ACTB levels in the sample and control cDNA, respectively. The sequences of primers and probes are listed in Table 2 .
Statistics P values were calculated using the Mann-Whitney U test or Fisher exact test to assess the associations between MI and various clinicopathologic characteristics. The association ENG  AGGGTTTTTTATTTAGTGATAAAGTTCGTGG  CTAACTCATCCAACCCGACCG  TCGGTTGGTAGGCGGTTTGGTTTAGT  60  MSP  MAL  AGTTTTTAGTTTTGGACGTTCGTAGCG  CGAAAAACCCGACCCGAACG  TCGAAGAGGTTTAGGGCGGTGTTCG  57  MSP  CAV1  CGAAGCGTTTGGGAGATATTTTAGAAAC  ATACTTTTAATAACACTCGTTTACATCTAATCG  AAACTTAAACAAACATACAAAATTTAACATTTCCCATC  57  MSP  TAC1  GGCGGTTAATTAAATATTGAGTAGAAAGTCGC  AAATCCGAACGCGCTCTTTCG  AGAATGTTACGTGGGTTTGGAGGTTTAAGGAG  60  MSP  SST  GGGGCGTTTTTTAGTTTGACGT  AACAACGATAACTCCGAACCTCG  AACGACTTATATACTCTCAACCGTCTCCCTCTA  60  MSP  NELL1  GGGTTTTTAGACGAACGTAGTCGTAGC  CCACCGCTAACGCGACGA  ACGACGTAAAACTCGAAACCCGACCC  60  MSP  AKAP12  GTTTTGTTAGAAACGGGAGGCGTTC  GAAACCAAAAACGCTACGACGCG  TCGGGTGGGCGGTTGTTTGGATT  60  MSP  ENG  AGCTTCCTCCTCCACTTCTACACA  CAGGTCAGGGCTGATGATGTTCAA  AGACCAGGAAGTCCATAGGACTGTCTTCAT  60  RT  MAL  CCTACATAGCCACTCTGCTCTACG  GCGGCCAGTTAACACCATCT  TCTTCATAAAGCCGCAGTAGAACTT  60  RT  CAV1  CCTCAACGATGACGTGGTCA  GGCCTTCCAAATGCCGT  TGAAGATGTGATTGCAGAACCAGAAGGGA  60  RT  TAC1  TGGTCCGACTGGTACGACAG 
Results
We conducted a comprehensive screen using a microarray and in silico scanning-based gene filtering procedure to identify novel genes inactivated via promoter hypermethylation in colon cancers (Figure 1 ). This gene-filtering process consisted of 4 steps: (1) microarray analysis to identify genes downregulated in primary colon cancers relative to normal colonic mucosae; (2) microarray analysis to identify genes up-regulated in colon cancer cells by 5-aza-dC treatment, an established global genomic DNA demethylating method; (3) in silico searching for genes with CpG islands overlapping their 5=-UTRs; and (4) in silico searching for genes with putative functional links to cancer.
Initially, we performed a cDNA microarray analysis comparing 7 normal colonic mucosae vs 12 MSI-H-or 15 MSS primary colon cancers; 1874 genes were down-regulated in either MSI-H or MSS cancers relative to normal colonic mucosae. Next, we performed a cDNA microarray analysis of 2 colon cancer cell lines, comparing the cells with vs without 5-aza-dC treatment. Eight hundred sixty-one genes were upregulated in at least 1 of these cell lines after 5-aza-dC treatment. By combining these 2 microarray analyses, we identified 274 genes with mRNA expression patterns that were appropriate for tumor-specific promoter methylation target genes. These 274 genes were down-regulated in primary colon cancers, and, simultaneously, these 274 genes were up-regulated in colon cancer cells after global DNA demethylation ( Figure 1 ). Our subsequent in silico search revealed that 214 of these 274 genes were autosomal genes with CpG islands overlapping their putative promoter regions. Furthermore, 54 within this 214-gene subset possessed functions that were potentially relevant to cancer ( Figure 1 , Table 3 ).
In support of our approach, 7 of these 54 genes had been reported to undergo promoter hypermethylation and mRNA down-regulation in human cancers in the literature: RUNX3, HLTF/SMARCA3, RAB32, AKAP12, CAV1, TDE/TMS1, and RRAD/REM3. RUNX3, HLTF/SMARCA3, RAB32 and TDE1/ TMS1 were hypermethylated in primary colon cancers, whereas AKAP12, CAV1 and RRAD/REM3 were hypermethylated in noncolonic cancers. 6,8 -13 Three genes, RUNX3, HLTF/SMARCA3, and RAB32, having been extensively studied before, were excluded from further study. Thus, the remaining 51 genes were designated as novel candidate methylation targets in colon cancer by our gene-filtering strategy.
We then assessed the promoter region methylation status of these 51 novel candidates in 14 colon cancer cell lines using MSP. Nine of these 51 genes demonstrated methylation in at least 1 of the 14 cell lines. These 9 genes were further analyzed in 34 primary colon cancers and 17 normal colonic mucosae for promoter region methylation status.
Two well-known neuroendocrine gastrointestinal peptide hormone genes, somatostatin (SST) and tachykinin-1 (TAC1), were among the 9 genes with promoter methylation in colon cancer cell lines. The promoter methylation status of SST and TAC1 was then analyzed in 34 primary cancers and 17 noncancerous colonic mucosae (Figure 2A ). Both SST (30 of 34 cases, 88%) and TAC1 (16 of 34 cases, 47%) were frequently methylated in primary colon cancers. Normal colonic mucosae also demonstrated some degree of methylation (SST, 8 of 17 cases, 47%; TAC1, 2 of 17 cases, 12%). However, the methylation levels of SST and TAC1 were significantly lower in normal colonic mucosae than in colon cancers (P Ͻ .001 and P ϭ .01, respectively, Mann-Whitney U test). We also observed increased SST and TAC1 methylation levels in cancers relative to matched normal Figure 1 . Outline of search for colon cancer-specific methylation target genes. This figure is an outline of our experiments, which consisted of 2 parts: the gene filtering for candidate methylation targets and the epigenetic validation. The gene-filtering part consisted of 2 sets of cDNA microarray experiments and a 2-step in silico genetic search. The first set of cDNA microarray experiments was performed to identify genes that were down-regulated in primary colon cancers relative to normal colonic mucosae. The second set of cDNA microarray experiments was to identify genes that were up-regulated in colon cancer cell lines after 5-aza-dC treatment (PostAzaC) relative to cells before the treatment (PreAzaC). Genes that were identified in both sets of cDNA microarray experiments were subjected to the subsequent selection using in silico search. The in silico search consisted of screenings for genes possessing (1) CpG island overlapping the 5=-UTR or the first exon and (2) putative tumor suppressive function. Candidate methylation targets meeting both of these selection criteria were then validated for the presence of promoter methylation in colon cancer cell lines and primary colon cancers using real-time quantitative MSP. Numbers in this figure represent the actual number of genes that fell into each of the corresponding categories.
colonic mucosae from the resection margins ( Figure 2B ). TAC1 methylation levels were significantly higher in Dukes stage A/B cancers than in Dukes stage C/D cancers (P ϭ .01, MannWhitney U test; Figure 3) . Similarly, SST methylation levels were significantly higher in MSI-L cancers than in MSS and MSI-H cancers (P ϭ .02, Mann-Whitney U test; Figure 3) . Age, gender, tumor site, or histologic differentiation were not significantly associated with methylation levels of SST or TAC1 (data not shown). Furthermore, we examined the correlation between promoter methylation and mRNA expression levels of SST and TAC1. For this purpose, we analyzed colon cancer cell lines with and without 5-aza-dC treatment using quantitative real-time PCR. mRNA up-regulation occurred for both SST and TAC1 after promoter DNA demethylation by 5-aza-dC treatment (Figure 4) .
In addition to SST and TAC1, hypermethylation of 5 other genes was detected in primary colon cancers by our epigenetic analysis of primary colon cancers and normal colonic mucosae: the protein kinase C-binding protein gene NELL1 (15/34, 44%), the scaffold protein gene caveolin-1 (CAV1, 34/34, 100%), the a-kinase anchoring protein gene AKAP12 (7/34, 21%), the transforming growth factor (TGF)-␤ receptor gene endoglin (ENG, 3/34, 9%), and the T-cell differentiation protein gene MAL (2/34, 6%) ( Figure 5) . Methylation of these genes in normal colonic mucosae was absent (ENG and MAL) or significantly less frequent than in primary cancers (AKAP12, CAV1, and NELL1; P ϭ .01, P Ͻ .001, and P Ͻ .001, respectively, Mann-Whitney U test). Age was not significantly associated with methylation levels in primary colon cancers for any of these genes (data not shown). For all 5 of these genes, mRNA was increased after promoter region DNA demethylation by 5-aza-dC treatment in a colon cancer cell line ( Figure 6 ).
Discussion
A comprehensive epigenetic survey based on differential mRNA expression detects hypermethylation events that are correlated with gene silencing. 14 By these means, our method allowed us to discover hypermethylation events that were biologically relevant to colon cancer. We previously reported a pilot study that identified a novel gene, RAB32, silenced by methylation in MSI-H colon cancer. 6 We now report complete search results of an extended target search in a large group of tumors. This genome-wide, 2-pronged search isolated 7 novel genes that were silenced via promoter methylation in colon cancer. Notably, 2 well-known growthregulatory gastrointestinal peptide hormones, SST and TAC1, were among these 7 novel methylation targets. To our knowledge, neither mutation nor promoter hypermethylation of SST and TAC1 in human cancer has been previously reported in the literature.
SST is a ubiquitously expressed hormone that regulates numerous endocrine systems, including the gastrointestinal tract. SST suppresses tumor growth indirectly through 3 mechanisms: regulating release of mitogenic hormones and growth factors, inhibiting neoplastic angiogenesis, and modulating the immune system. 3 SST directly suppresses cell growth in an autocrine manner, principally via SST receptor type 2, which is widely expressed in both normal and cancerous colonic epithelial cells. 15, 16 The ubiquitous SST hypermethylation observed in the current study suggests that inactivation of this direct growth suppression is important in colon tumorigenesis. In addition, SST was significantly more methylated in MSI-L cancers than in the combined group of MSS and MSI-H cancers in our series of tumors. The biologic distinction of MSI-L from MSS tumors has been a subject of active debate, partially because causative genetic abnormalities unique to MSI-L cancers have not been identified. 17 However, there have been reports illustrating unique clinical and molecular properties of MSI-L cancers, such as a poor prognosis, frequent MGMT methylation, and differing global gene expression profiles. 5, 18 Thus, the high SST methylation level that we observed in the current study provides additional evidence supporting the discrete molecular and clinicopathologic phenotype of MSI-L cancers.
TAC1 is a precursor for multiple hormones, including substance P (SP) and neurokinin A. These molecules affect secretion, motility, and inflammatory reactions of the gastrointestinal tract via activation of their receptors, neurokinin-1 and -2 receptors (NK1 and NK2). 19 SP has been reported to be proliferative and antiapoptotic by activating mitogen-activated protein kinase cascade and nuclear factor-B. 20, 21 However, a recent report demonstrated that SP mediates nonapoptotic programmed cell death. 22 SP also potentiates cytotoxicity of lymphokine-activated killer cells against colon cancer cells. 23 In addition, another TAC1 gene product, neurokinin A, has been reported to exert antiproliferative effects. 24 Therefore, TAC1 gene products play complex biologic roles in colon cancer pathophysiology. The prevalent TAC1 hypermethylation in localized cancers observed in the current study may indicate that TAC1 silencing promotes early stage carcinogenesis by aiding tumor cells to escape immune surveillance and autocrine growth-inhibitory signaling.
In the current study, 5 additional novel genes were identified to undergo promoter methylation in primary colon cancers: NELL1, ENG, MAL, AKAP12, and CAV1. To our knowledge, NELL1, ENG, and MAL have never been reported to suffer methylation-mediated gene silencing in any physiologic or biologic context. AKAP12 and CAV1 have been recently reported to become methylated in noncolonic cancers. 8, 9, 25 All 5 of these genes possess putative functional links to cancer. NELL1 is a protein kinase C-binding protein that is required for osteoblast differentiation, and its overexpression promotes apoptosis in osteoblasts. 26, 27 The high prevalence of its promoter methylation in colon cancer suggests the potential role of NELL1 inactivation in colon tumorigenesis. ENG is a TGF receptor subunit gene that is down-regulated in many human tumors, and its reexpression suppresses tumor invasion and migration. 28, 29 MAL is an endoplasmic reticulum membranous protein that participates in T-cell differentiation and T-cell receptor signaling. 30 Interestingly, MAL cooperates with CAV1, another candidate tumor suppressor identified in the current study. 31 AKAP12 is a protein kinase A-and C-binding protein that coordinates the intracellular signaling of these 2 protein kinases and is an inhibitor of v-src-mediated transformation. 32 CAV1 coordinates diverse extracellular and intracellular signaling processes. CAV1 down-regulation transforms cells via p42/44 MAP kinase cascade activation, and reconstitution of CAV1 suppresses the growth of tumor cells. 33, 34 In summary, we successfully applied a differential expression-based gene filtering procedure to identify novel genes that are uniquely inactivated in colon cancer via promoter methylation. As a result, we found 7 novel genes that are targets of epigenetic silencing in colon cancer. Interestingly, 2 of these novel targets are gastrointestinal endocrine peptides, SST and TAC1. This finding serves as novel epigenetic evidence that SST and TAC1 participate in the suppression of colon carcinogenesis and/or tumor progression. Further analyses of these genes are indicated not only to understand Methylation index (MI) represents the ratio of densely methylated DNA in the sample at the target sequence relative to the fully methylated positive control DNA. Primary colon cancers were significantly more methylated than were normal colonic mucosae for both SST and TAC1 (P Ͻ .001 and P ϭ .01, Mann-Whitney U test). Circle, sample belonging to over the 90th or below the 10th percentile range; whisker, 10th or 90th percentile value; rectangle box, range for 25th to 75th percentile; black square, median value. Measurement of MI was performed using real-time quantitative MSP, and a CpG-free ␤-actin genomic sequence was used for normalization. (B) These line graphs display MI at the SST-and TAC1-promoter regions for matching normal colonic mucosae (left-side data point) and colon cancers (right-side data point) from 6 patients. An increased promoter methylation level was observed for SST in all 6 (100%) and TAC1 in 4 (67%) of 6 cases. better their biologic roles in colon carcinogenesis, but also to evaluate them as biomarkers of early detection and prognostication. In addition, the 5 other methylation targets identified here are also promising as tumor suppressor gene candidates and deserve further study in these contexts. Our genome-wide, multipronged search strategy offers the potential to discover additional methylation events in additional cancer types, and its application may provide further insights 
